Consolidation Immunotherapy With Blinatumomab Improves Survival in B-ALL

March 25, 2020

In an interview with Targeted Oncology, Patrick Brown, MD, discussed the results from the randomized phase III study evaluating blinatumomab in patients with B-acute lymphoblastic leukemia.

Venetoclax Combination Improves OS in Acute Myeloid Leukemia

March 23, 2020

Venetoclax in combination with azacytidine demonstrated a statistically significant improvement in overall survival and achieved a satisfactory composite complete remission rate in previously untreated patients with acute myeloid leukemia, meeting the co-primary end points of the phase III VIALE-A study. Genentech, the developer of venetoclax, announced the positive news in a press release, also noting that safety profiles of both drugs were consistent with prior reports.

Positive Efficacy Achieved With Bendamustine Debulking Followed by Ofatumumab /Ibrutinib in CLL

March 19, 2020

Bendamustine debulking followed by ofatumumab and ibrutinib demonstrated an overall response rate of 92% in patients with chronic lymphocytic leukemia, meeting the primary end point of the phase II CLL2-BIO trial, and was well-tolerated with no new safety signals. Results from the study were published in Haematologica.

86% Remission Rate Observed in Chemotherapy and ARC Combination in Relapsed/Refractory AML

March 11, 2020

After demonstrating promising results that were comparable to targeted therapies in the first 2 cohorts of a phase I clinical trial, the combination of cladribine, cytarabine, granulocyte-colony stimulating factor, and mitoxantrone plus the antibody radiation conjugate lintuzumab-Ac225 in patients with relapsed/refractory acute myeloid leukemia is now being explored in a third cohort.

Current Regimens Being Investigated in Chronic Lymphocytic Leukemia

March 05, 2020

Alexey V. Danilov, MD, PhD, discusses important studies in the chronic lymphocytic leukemia space and questions whether combination or sequential therapy is better for patients with chronic lymphocytic leukemia.

The Role of BTK Inhibitors Evolve for the Treatment of Patients With CLL

March 05, 2020

In an interview with Targeted Oncology, Alexey V. Danilov, MD, PhD, discussed the ELEVATE-TN trial and other potentially practice-changing BTK inhibitor combinations expected to emerge in chronic lymphocytic leukemia.

Venetoclax Plus Low-Dose Cytarabine Fails to Improve OS in AML

March 03, 2020

The combination of venetoclax plus low-dose cytarabine did not demonstrate a statistically significant improvement in overall survival compared with LDAC plus placebo in patients with acute myeloid leukemia who were ineligible for intensive chemotherapy at the time of a planned analysis, missing the primary end point of the phase III VIALE-C trial.

SIERRA Trial: Background on the Iomab-B Combination in Relapsed/Refractory AML

February 19, 2020

In an interview with Targeted Oncology, Rajneesh Nath, MD, discussed the background and rationale for the phase III SIERRA trial. He also explained what this research means for the treatment landscape of acute myeloid leukemia.

Adverse Events Differ Among BTK Inhibitors in CLL

February 14, 2020

Jeff P. Sharman, MD, discusses what differentiates acalabrutinib from other BTK inhibitors available in chronic lymphocytic leukemia.

Predictive Value of Select Gene Mutations Demonstrated in Phase III CLL Study

February 11, 2020

Next-generation sequencing in patients with chronic lymphocytic leukemia treated with the combination of chlorambucil and ofatumumab showed that the presence of TP53, SF3B1, and NOTCH1 mutations were predictive of reduced efficacy, according to the results of the phase III COMPLEMENT1 trial published in Haematologica.